Per 2.5/500 mg FC tab Linagliptin 2.5 mg, metformin HCl 500 mg. Per 2.5/850 mg FC tab Linagliptin 2.5 mg, metformin HCl 850 mg. Per 2.5/1,000 mg FC tab Linagliptin 2.5 mg, metformin HCl 1,000 mg
Indications/Uses
Adjunct to diet & exercise to improve glycaemic control in adults w/ type 2 DM when treatment w/ both linagliptin & metformin is appropriate, in patients already being treated & well controlled w/ the free combination of linagliptin & metformin. In combination w/ an SGLT2 inhibitor (ie, triple combination therapy) as an adjunct to diet & exercise in patients inadequately controlled on their max tolerated dose of metformin (≥1,500 mg/day) & an empagliflozin.
Do not use in patients w/ type 1 diabetes or for the treatment of diabetic ketoacidosis. Hypoglycemia. Lactic acidosis. Monitor renal function before initiation of therapy & regularly thereafter. Renal impairment during initiating antihypertensive or diuretic & NSAID therapy. Discontinue use 48 hr before elective surgery w/ general, spinal or peridural anaesth, & if pancreatitis is suspected. Change in clinical status of patients w/ previously controlled type 2 diabetes. Pregnancy & lactation. Childn <18 yr. Elderly.
Sign Out
